Navigation Links
New vaccine to assist worldwide eradication of polio
Date:12/14/2010

Scientists at the University of Leeds are joining the global fight to eradicate polio by developing a new type of vaccine that can trick the body to develop immunity against the disease.

The project has been awarded $500,000 from the Bill and Melinda Gates Foundation, through the World Health Organisation, and aims to be effective against all polio subtypes.

Led by Professor Dave Rowlands and Dr Nicola Stonehouse from the University's Faculty of Biological Sciences, the research team will design a replica virus particle that looks and behaves like the real virus, but is actually an empty protein shell.

The researchers believe the hoax virus will trigger the body's immune system, but because it does not contain the genetic blueprint that replicates the virus inside the body, has no chance of causing or helping to spread the disease.

"This is an entirely new strategic approach against polio," says Dr Stonehouse. "This project is not about improving the efficiency of the current types of vaccine. Our intention is to design and produce a replica virus particle that carries no RNA cargo. This means it will be entirely safe to use as it can't ever cause the disease, and unlike current vaccines, can be produced without needing to grow large amounts of the infectious virus."

The team, led by Leeds, brings together researchers from Harvard University, the University of Oxford and the UK's National Institute for Biological Standards and Control (NIBSC), a centre of the Health Protection Agency. The first stage of the research will focus on proving that that the new approach is viable against the virus.

Current polio vaccines in use around the world are either delivered orally or injected, but contain either a weakened form of the virus, or an inactivated virus to kickstart the immune response. Whilst these have been extremely successful in reducing polio globally, the virus persists in several countries and unexpected outbreaks still occur.

"What excites me about this project is that we're working towards a risk-free vaccine that will be essential for the complete eradication of polio from the globe," adds Dr Stonehouse. "As well as being safe to produce and use, it will be stable enough not to need refrigeration and could be injected as part of current childhood vaccination programmes."

Although a similar approach using replica virus particles has been used successfully to create the human papilloma virus (HPV) vaccine against cervical cancer, the complexity of the polio virus creates significant additional challenges.

"With polio, the virus particle's surface matures and changes because of the genetic material inside, and so ensuring that our replica particle mimics this surface exactly is not going to be easy. Since it's essentially an empty protein shell, it also has to be robust enough that it doesn't fall apart," explains Professor Rowlands. "This will be an iterative process, where we keep testing, refining and improving the particles we design until we achieve exactly the right structure and surface."

"We believe that if the project is successful, this new approach could help to completely eradicate this disease for good."


'/>"/>

Contact: Dr Nicola Stonehouse
n.j.stonehouse@leeds.ac.uk
44-113-343-3102
University of Leeds
Source:Eurekalert  

Related biology news :

1. Childrens National researchers develop novel anti-tumor vaccine
2. RNA molecules, delivery system improve vaccine responses, effectiveness
3. Bird flu vaccine protects people and pets
4. Research identifies type of vaccine that holds promise in protecting against TB
5. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
6. Flu shot protects kids -- even during years with a bad vaccine match
7. New type of vaccines deliver stronger and faster immune response
8. Fractional dose of scarce meningitis vaccine may be effective in outbreak control
9. Vaccines and autism: Many hypotheses, but no correlation
10. New vaccine developed for preventing uncommon cold virus
11. African-Americans aware and accepting, but often do not receive, the HPV vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New vaccine to assist worldwide eradication of polio
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Surgical Wound Market with the addition of its newest module, US Hemostats & ... market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
Breaking Biology Technology: